加载中
AMEXHealthcareMedical - Devices
最新数据
US$2.33
−US$0.19 · -7.54%
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.
常规交易时段
US$2.33
−US$0.19 · -7.54%
盘中时间采用ET。市场数据可能有所延迟。
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.
日内区间
当前US$2.33
52周区间
当前US$2.33
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
14
估值过高
情绪
48
多空交织
风险
75
高风险
动量
34
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds. This treatment is specifically utilized for a broad range of cancers, such as those impacting the prostate, brain, lung, head and neck regions, gynecological system, pelvic/abdominal areas, and colorectal tissues. The company distributes its products to medical facilities and physician practices equipped with surgical capabilities. The entity originally operated under the name Isoray, Inc., before officially adopting the name Perspective Therapeutics, Inc. in February 2022. Founded in 1998, the company maintains its corporate headquarters in Richland, Washington.
日内区间
当前US$2.33
52周区间
当前US$2.33
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | 145.4万 USD | 143.4万 USD | 541.5万 USD | 1079.5万 USD |
| 销货成本 | — | 230.6万 USD | — | 304.8万 USD | 617.9万 USD |
| 毛利 | — | −85.2万 USD | 143.4万 USD | 236.7万 USD | 461.6万 USD |
| 研究与开发 | 8421.5万 USD | 3933.2万 USD | 2131.1万 USD | 181.3万 USD | 258.2万 USD |
| 销售、一般及管理费用 | 3023.3万 USD | 2661.3万 USD | 2106.4万 USD | 935.2万 USD | 942.5万 USD |
| 营业费用 | 1.14亿 USD | 6594.5万 USD | 4237.5万 USD | 1147万 USD | 1200.7万 USD |
| 利息收入 | 811.4万 USD | 1051.5万 USD | 93.4万 USD | 112.2万 USD | 11.9万 USD |
| 利息支出 | 37.6万 USD | 4.8万 USD | 8.4万 USD | — | — |
| 折旧和摊销 | 325.1万 USD | 230.6万 USD | 98.6万 USD | 32.4万 USD | 24.8万 USD |
| 营业利润 | −1.14亿 USD | −6679.7万 USD | −4094.1万 USD | −910.3万 USD | −739.1万 USD |
| 净利润 | −1.03亿 USD | −7927.9万 USD | −4650.8万 USD | −1076万 USD | −727.2万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$11.00
上涨空间 372.10%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1046.93万0.00%2.3万亿 USD0.03%US$380.45-0.29%
iShares Russell 2000 ETFIWM663.99万0.01%787.4亿 USD0.19%US$276-0.68%
Vanguard Extended Market ETFVXF312.38万0.00%954亿 USD0.05%US$231.7-0.78%
iShares Russell 2000 Value ETFIWN244.35万0.02%137.49亿 USD0.24%US$210.42-0.32%
Vanguard Russell 2000 ETFVTWO187.17万0.01%180亿 USD0.06%US$111.47-0.71%
iShares Biotechnology ETFIBB176.95万0.02%108.2亿 USD0.44%US$201.22-1.49%
Dimensional - US Small Cap ETFDFAS159.71万0.00%338.04亿 USD0.31%US$77.91-0.33%
Schwab U.S. Small-Cap ETFSCHA116.35万0.01%217.13亿 USD0.03%US$32.445-0.66%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Value ETFIWNVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBDimensional - US Small Cap ETFDFASSchwab U.S. Small-Cap ETFSCHAAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
